anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

212,641-212,700 of 319,975

filter-aware
16
Waterfall plot uses standard clinical trial terminology (PD, SD, PR). Comparison table highlights the study drug's performance against Dacarbazine and Binimetinib.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
17
The slide uses a before-and-after visual comparison to demonstrate clinical efficacy.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
18
Swimmer plot visualization of clinical trial data (Trial LXH254X2102).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
19
The slide highlights consistent clinical activity across two study phases, culminating in a combined ORR of 33.3%.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
20
Swimmer plot visualization of clinical trial data.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
21
The diagram uses a tree structure to categorize patient outcomes (off treatment vs on treatment, further broken down by SD and PR).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
22
The chart displays adverse events occurring in >=10% of patients (n=15).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
23
CoC = Cost of Care (or standard of care context); FIH = First-in-Human; PTS = Probability of Technical Success; CDP = Clinical Development Plan.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
24
The slide uses a biological signaling pathway map to justify combination therapy strategy.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
25
The diagram shows the RAS/MAPK signaling pathway. The table provides a breakdown of patient populations for specific indications.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
26
Erasca | Investor Presentation Deck | 56 slidesErasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
27
The diagram shows the signaling pathway with specific drug targets highlighted.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
28
Data shows tumor volume over time for various treatment groups including monotherapy and combinations.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
29
Includes waterfall plot (left) and swimmer plot (right) with specific response rates and disease control rates.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
30
Data cut 23MAR2023. Table shows frequency of specific adverse events by severity grade and dosage cohort.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
31
The slide uses a process-oriented flow to demonstrate clinical validation milestones.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
32
The slide uses arrows to visually indicate performance superiority of ERAS-601 over RMC-4550.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
33
Data presented as tumor volume over time (days) with error bars representing SEM.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
34
Includes RECIST 1.1 criteria reference and specific tumor measurements over time.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
35
The table displays counts and percentages of patients experiencing specific adverse events, categorized by severity (All vs Grade >= 3).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
36
The diagram shows the EGFR signaling pathway leading to MAPK and PI3K pathways.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
37
The slide uses a stacked bar chart to show mutation incidence and a comparison table to highlight clinical trial failures in GBM despite success in other indications.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
38
The slide uses Western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
39
The chart shows a statistically significant (***) improvement in survival for the ERAS-801 group compared to the control and other standard-of-care inhibitors.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
40
The slide presents four separate survival plots (HK301, GS025, HK336, GS187) comparing vehicle control to ERAS-801 treatment.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
41
The slide uses a waterfall plot to show individual model responses, with a heatmap below for patient characteristics (recurrence, sex, methylation status).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
42
The slide uses a table format to communicate a product development roadmap.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Quick Win Big Bet1 hit
43
Erasca | Investor Presentation Deck | 56 slidesErasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Quick Win Big Bet1 hit
44
Features the Lorenz attractor graphic, which is a signature visual for Erasca.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Quick Win Big Bet1 hit
45
The slide uses a structured comparison between preclinical and clinical assets, with a specific callout for the lead asset (Naporafenib).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
46
The diagram uses a bullseye/concentric circle metaphor to represent strategic focus areas.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
47
The slide uses a contrast-based layout to frame the subject as a winner in a difficult therapeutic space.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
48
The slide uses western blot data to demonstrate the efficacy of ERAS-007 in a specific biological pathway context.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
49
The slide uses a before-and-after imaging comparison to show clinical efficacy.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
50
The chart displays individual patient responses categorized by dose level, with a list of specific notable responses on the right.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
51
The chart displays patient-level data including cancer type, mutation, weekly dose, and response status (Partial Response, Stable Disease, Progressive Disease).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
52
Data from HERKULES-1 study, cutoff 23 May 2022.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
53
The slide compares various dosing schedules (QW, BID-QW, BIW) against IC90 and IC50 thresholds.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
54
The slide uses a comparison frame to position ERAS-601 against competitors like Novartis, Revolution Medicines, Jacobio, Genentech, Pfizer, and Merck.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
55
The slide uses a biological pathway diagram to illustrate the mechanism of action.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
56
The slide compares two different drug candidates' PK profiles against IC50 and IC90 thresholds.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
01
Slide 1
Etsy | Investor Presentation Deck | 34 slidesEtsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations 1 hit
02
Includes page number 2 in top right corner.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations 1 hit
03
The slide uses a 2-column layout with icons to present four distinct pillars of the company's value proposition.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · Problem1 hit
04
The slide uses a 'House of Brands' strategy framework to present GMS data.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · Problem1 hit
05
The slide uses a circular flywheel diagram to represent the network effects of the marketplace.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · Solution1 hit
06
Includes seller census data and growth metrics.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a grid of product images as a background to reinforce the 'unique products' message.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · Solution1 hit
08
Etsy | Investor Presentation Deck | 34 slidesEtsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a split-screen layout contrasting technical search methodology with user-centric quality goals.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · Solution1 hit
10
The slide uses a process flow at the bottom to illustrate the impact of the initiative.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · Solution1 hit
11
Etsy | Investor Presentation Deck | 34 slidesEtsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
12
The slide highlights efficiency gains by showing marketing spend as a percentage of revenue decreasing to 26% in Q2 23.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
13
The slide uses a visual flow diagram to map marketing channels to the customer journey.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
14
The slide uses two charts to demonstrate marketing efficiency and buyer behavior evolution.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
15
The slide uses a vertical additive stack to explain the components of GMS growth.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
16
Etsy | Investor Presentation Deck | 34 slidesEtsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
17
The slide uses a waterfall chart to explain revenue growth and a combo chart for EBITDA performance.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
The chart shows negative growth rates that are trending toward zero, which the company frames as 'the right direction'.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
19
The slide uses a 2x3 grid of icons and text to highlight performance improvements.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit